Relapses are a hallmark of multiple sclerosis (MS). 1 Current definition criteria for relapses in clinical trials include a disturbance of function that lasts a minimum of 24-48 hours of symptom duration and changes in functional measures assessed by disability and functional scores. 1 MS relapses reflect the formation of new inflammatory activity or reactivation of previously existing activity located in any segment of the central nervous system (CNS). 2 Activation of the immune process is initiated systemically, resulting in migration of activated immune cells into the CNS, where they are reactivated and result in parenchymal inflammation. 1 The acute inflammation in MS is characterized by infiltration of activated lymphocytes, macrophages, and microglia, with involvement of cortex, white matter, and deep gray matter with myelin, axonal and neuronal destruction, and synaptic loss, astroglial reaction, remyelination, and synaptic rearrangement. 3 The relapse activity, reflecting CNS inflammation and demyelination in the course of MS, may propagate future disability progression; therefore, this activity should be treated when identified (to obtain a rapid resolution of the inflammatory process) and be prevented by specific treatment strategies to avoid disease progression. 1-3 The acute treatment most used for relapses currently consists of high-dose intravenous methylprednisolone (IVMP), usually administered at 1 g/ daily in a single cycle lasting 3-5 days. 1 The presence of new lesions on magnetic resonance imaging (MRI) (new T2 or contrast-enhanced lesion (CEL)) in MS patients reflects a new inflammatory process. 2 Indeed, MRI can detect focal and diffuse white matter demyelination, gliosis and edema, acute inflammation with blood-brain barrier dysfunction, as well as persistent tissue loss in an everyday clinical practice setting. 4 In this context, beyond new T2 or CEL, other characterized MRI markers of tissue damage is the persistent T1-hypointense lesion, also called persistent "black holes" (pBHs). 4, 5 Although the definition of pBHs is not univocal, at present there is consensus that defines pBHs as T1-hypointensities persisting for more than 6 months after their appearance. 4 PBHs reflect a region of axonal loss and irreversible parenchymal destruction, suggesting that they may contribute to permanent neurologic deficits in MS. 4 Several studies have shown that specific CEL correlate with an increased risk of conversion to pBHs. 6 Likewise, it is also worth mentioning that the presence of new asymptomatic lesions on brain MRI scans have been shown to predict recurrence of relapses. This supports the use of MRI activity as clinical surrogates both in trials and, to some extent, at the clinical practice. 2 To summarize, the presence of an asymptomatic new lesion in the absence of clinical dysfunction cannot be defined as a relapse in that specific term. However, there is evidence that a new lesion on MRI signals a new inflammatory process that leads to tissue damage which, in many cases, could also lead to pBHs development associated with disability and disease progression in MS.
The presence of new lesions on magnetic resonance imaging (MRI) (new T2 or contrast-enhanced lesion (CEL)) in MS patients reflects a new inflammatory process. 2 Indeed, MRI can detect focal and diffuse white matter demyelination, gliosis and edema, acute inflammation with blood-brain barrier dysfunction, as well as persistent tissue loss in an everyday clinical practice setting. 4 In this context, beyond new T2 or CEL, other characterized MRI markers of tissue damage is the persistent T1-hypointense lesion, also called persistent "black holes" (pBHs). 4, 5 Although the definition of pBHs is not univocal, at present there is consensus that defines pBHs as T1-hypointensities persisting for more than 6 months after their appearance. 4 PBHs reflect a region of axonal loss and irreversible parenchymal destruction, suggesting that they may contribute to permanent neurologic deficits in MS. 4 Several studies have shown that specific CEL correlate with an increased risk of conversion to pBHs. 6 Likewise, it is also worth mentioning that the presence of new asymptomatic lesions on brain MRI scans have been shown to predict recurrence of relapses. This supports the use of MRI activity as clinical surrogates both in trials and, to some extent, at the clinical practice. 2 To summarize, the presence of an asymptomatic new lesion in the absence of clinical dysfunction cannot be defined as a relapse in that specific term. However, there is evidence that a new lesion on MRI signals a new inflammatory process that leads to tissue damage which, in many cases, could also lead to pBHs development associated with disability and disease progression in MS.
Acute relapse management with high doses of corticosteroids have proven to be effective in relapses by shortening the duration of disability associated with their course as well as by decreasing the inflammatory cycle faster and better. 1, 7 The treatment acts in a number of ways, including, dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasation of immune cells into the CNS, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and TNF-a. 7 Regarding the effect that high doses of corticosteroids have on MRI parameters, current research demonstrates that acute management of new T2 or CEL with high doses of corticosteroids reduces the number, volume, and time in which CEL lesions persist, lowers the risk of pBHs formation and T1 lesion volume increase, and decreases the probability of brain atrophy during the follow-up. 4, 5, [8] [9] [10] This
An asymptomatic new lesion on MRI is a relapse and should be treated accordingly -Yes
DT Chard and SA Trip evidence suggests that high doses of corticosteroids could be an independent protective factor against tissue destruction produced by new inflammatory lesions observed in MRI.
Given that in MS the immunological processes are thought to drive neuro-axonal loss, high doses of corticosteroid administration, due to the strong and unspecific anti-inflammatory effect, could have a positive impact on asymptomatic MRI lesion evolution. Thus, high doses of corticosteroids could have beneficial implications in clinical practice, since it is possible to hypothesize that the treatment of patients with new T2 or CELs could reduce the probability of CNS tissue loss by counteracting the detrimental effect of CNS inflammation. 7 Based on the aforementioned research, an asymptomatic new lesion on MRI should be considered as a relapse and treated accordingly. However, further studies on larger cohorts are required to confirm the effectiveness of this intervention in clinical practice.
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